CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 38 enrolled
Drug / intervention
Cabozantinib +2 moredrug
Likely dose
Cabozantinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04322955
NCT04322955Phase 2Active
CompareCT.gov

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)

Mark Stein·interventional·Posted Mar 26, 2020·Updated Jun 5, 2026

In Brief

A Phase 2 clinical trial evaluating Cabozantinib, Nivolumab, and 1 other intervention for Kidney Cancer and Renal Cell Carcinoma. Active but no longer recruiting, targeting 38 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer, Renal Cell Carcinoma
CountriesUnited States
CollaboratorsExelixis, Bristol-Myers Squibb

Timeline

Phase 2Active
20212022202320242025202620272028
First PostedMar 26, 2020
Enrollment StartJun 22, 2020
Primary CompletionMay 1, 2027
Study CompletionFeb 1, 2028
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 6.3 years agoPrimary completion in 10 months

Interventions

Cabozantinibdrug

2 x 20 mg capsules taken orally daily

Nivolumabdrug

480mg IV on first day of each 28-day cycle

Cytoreductive nephrectomyprocedure

Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.